PROGENTAC

PROGENTAC (Proteolysis Gene Silencing Targeting Chimera) is a programmable, dual-functional therapeutic platform that integrates gene-silencing antisense oligonucleotides (ASOs) with a DNA-templated protein-degrading chimera (DTAC). This technology is designed to achieve precise, context-dependent control of biological processes by combining the digital genetic code of nucleic acids with analog molecular interactions. The molecular framework consists of three primary elements: a DNA-templated, spatially controlled protein-degrading chimera (DTAC) platform; an ASO for targeted gene modulation; and a conditional nucleic acid-based molecular framework that regulates activity in response to disease-specific intracellular cues or chemical triggers. In preclinical proof-of-concept studies, PROGENTAC demonstrated potent activity against the Cyclin D1-CDK4/6 complex in cancer cell lines (U251, A549, and AU565) with a DC50 in the 20-100 nM range. The ASO component utilizes chemical modifications such as 2'-OMe, locked nucleic acid (LNA), and phosphorothioate (PS) backbones to enhance stability and potency.

Other names

Proteolysis Gene Silencing Targeting Chimera